Skip to search formSkip to main contentSkip to account menu

avagacestat

Known as: (2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide, Pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2R)- 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The toxicity of avagacestat, a sulfonamide-based gamma (γ)-secretase inhibitor that was in development as a treatment for… 
Highly Cited
2015
Highly Cited
2015
IMPORTANCE Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to… 
Highly Cited
2015
Highly Cited
2015
Hepatic stellate cells (HSCs) known as “master producers” and macrophages as “master regulators”, are the key cell types that… 
Review
2014
Review
2014
The prevailing theory regarding Alzheimer disease (AD) is that insoluble amyloid β‐peptide (Aβ) plays a critical role in the… 
Highly Cited
2013
Highly Cited
2013
A hallmark of Alzheimer’s disease (AD) pathology is the accumulation of brain amyloid β-peptide (Aβ), generated by γ-secretase… 
2013
2013
AIM To evaluate the single dose pharmacokinetics, pharmacodynamics, and preliminary tolerability of the γ-secretase inhibitor BMS… 
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor… 
2012
2012
Background and ObjectivesAvagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis… 
Highly Cited
2012
Highly Cited
2012
The "Notch-sparing" γ-secretase inhibitor (GSI) BMS-708,163 (Avagacestat) is currently in phase II clinical trials for Alzheimer… 
2012
2012
BackgroundThe concentration of amyloid β (Aβ) peptides in cerebrospinal fluid (CSF) is a biomarker for Alzheimer’s disease (AD…